Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome
Information
- Disease name
- Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03953898 | Active, not recruiting | Phase 2 | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | August 4, 2020 | December 1, 2024 |
| NCT04190550 | Active, not recruiting | Phase 1 | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | February 4, 2021 | June 30, 2025 |
| NCT01139970 | Active, not recruiting | Phase 1 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | May 21, 2010 | February 22, 2025 |
| NCT03874052 | Active, not recruiting | Phase 1 | Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | August 16, 2019 | December 31, 2024 |
| NCT04915612 | Active, not recruiting | Phase 1 | Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia | May 21, 2021 | May 1, 2025 |
| NCT02530034 | Active, not recruiting | Phase 1 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | January 31, 2019 | January 31, 2026 |
| NCT04284787 | Active, not recruiting | Phase 2 | BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia | February 16, 2021 | August 1, 2024 |
| NCT02658487 | Active, not recruiting | Phase 2 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia | March 2016 | September 2024 |
| NCT03747757 | Active, not recruiting | Phase 2 | Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue | November 29, 2018 | September 11, 2025 |
| NCT01885689 | Active, not recruiting | Phase 2 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | February 10, 2014 | December 30, 2024 |
| NCT00392353 | Active, not recruiting | Phase 1/Phase 2 | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | November 22, 2006 | September 30, 2024 |
| NCT03404193 | Active, not recruiting | Phase 2 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | January 18, 2018 | December 31, 2024 |
| NCT03330821 | Active, not recruiting | Phase 1/Phase 2 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | April 18, 2018 | October 13, 2025 |
| NCT03289910 | Active, not recruiting | Phase 2 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | September 24, 2018 | December 21, 2024 |
| NCT02960646 | Completed | Phase 1 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | January 18, 2017 | February 13, 2023 |
| NCT03096782 | Completed | Phase 2 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | October 13, 2017 | September 20, 2022 |
| NCT00070135 | Completed | Phase 2 | Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission | January 2004 | June 15, 2016 |
| NCT00093470 | Completed | Phase 3 | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission | August 18, 2004 | |
| NCT00313586 | Completed | Phase 2 | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | August 2006 | July 2013 |
| NCT01132586 | Completed | Phase 1 | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | May 2010 | January 2014 |
| NCT01238211 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | December 14, 2010 | March 15, 2021 |
| NCT01420926 | Completed | Phase 2 | Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia | November 16, 2011 | April 1, 2021 |
| NCT01664897 | Completed | Phase 2 | Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 16, 2013 | October 25, 2018 |
| NCT01757639 | Completed | Phase 1 | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | December 14, 2012 | |
| NCT01823198 | Completed | Phase 1/Phase 2 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | June 11, 2013 | May 10, 2022 |
| NCT01904136 | Completed | Phase 1/Phase 2 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | April 22, 2014 | February 28, 2022 |
| NCT02286726 | Completed | Phase 2 | CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia | May 4, 2015 | January 22, 2020 |
| NCT02397720 | Completed | Phase 2 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | April 7, 2015 | October 9, 2023 |
| NCT02509546 | Completed | Phase 1/Phase 2 | 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | September 2, 2015 | March 16, 2021 |
| NCT02532231 | Completed | Phase 2 | Nivolumab in AML in Remission at High Risk for Relapse | October 19, 2015 | August 8, 2023 |
| NCT03813147 | Completed | Phase 1 | Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 17, 2019 | December 31, 2023 |
| NCT05554419 | Not yet recruiting | Phase 2 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | August 16, 2024 | January 31, 2025 |
| NCT03672539 | Recruiting | Phase 2 | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | November 7, 2018 | November 30, 2025 |
| NCT03630991 | Recruiting | Phase 1 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | October 11, 2018 | April 30, 2025 |
| NCT04269213 | Recruiting | Phase 2 | CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old | July 29, 2021 | January 29, 2025 |
| NCT04214249 | Recruiting | Phase 2 | BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | February 17, 2021 | July 31, 2024 |
| NCT03128034 | Suspended | Phase 1/Phase 2 | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | October 24, 2017 | March 31, 2027 |
| NCT03670966 | Suspended | Phase 1/Phase 2 | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | July 10, 2019 | March 20, 2027 |
| NCT00589316 | Terminated | Phase 1 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome | October 5, 2007 | October 1, 2021 |
| NCT03146871 | Terminated | Phase 2 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | April 20, 2017 | March 27, 2019 |
| NCT03519984 | Terminated | Phase 1 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | May 9, 2018 | November 24, 2020 |
| NCT02953561 | Terminated | Phase 1/Phase 2 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | February 20, 2017 | September 30, 2019 |
| NCT02399917 | Terminated | Phase 2 | Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | April 20, 2015 | July 12, 2018 |
| NCT02038153 | Terminated | Phase 1/Phase 2 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | December 2013 | January 2016 |
| NCT01620216 | Terminated | Phase 2 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | May 11, 2012 | April 30, 2017 |
| NCT01260714 | Terminated | Phase 1 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | December 2010 | June 2015 |
| NCT03602898 | Withdrawn | Phase 2 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | June 1, 2021 | September 17, 2023 |